Articles On Impression Healthcare (ASX:IHL)

It’s late in the day on the 1st of December, which means not only is it 24 sleeps until Christmas, but it’s also a good chance to put your feet up for the day, count your blessings (I counted mine – I have six!) and relax while we bring you...

Clinical stage pharmaceutical cannabinoid and psychedelics company Incannex has engaged Eurofins to manufacture ReneCann Therapeutic Topical Application for immune disordered skin diseases. Incannex Healthcare (ASX:IHL) has again teamed wit...

Incannex Healthcare (ASX: IHL) will begin manufacturing its ReneCann therapeutic for clinical trials evaluating it in dermatological conditions caused by immune system disorders including vitiligo, psoriasis and atopic dermatitis (also refe...

Incannex Healthcare (IHL) engages Eurofins Scientific to manufacture IHL’s ReneCann product for skin diseasesEurofins will produce the topical treatment to be used in clinical trials to confirm the safety and therapeutic effect of the drug...

Incannex is teaming with Eurofins to help people with opioid and nicotine addiction disorders, by undertaking formulation development and manufacture of CannQuit-N and CannQuit-O. Incannex Healthcare (ASX:IHL) has engaged multinational cont...

Incannex Healthcare (IHL) teams up with Luxembourg-based Eurofins Scientific to manufacture two chewable products designed to treat nicotine and opioid addictionEurofins will manufacture Incannex’s CannQuit products — chewing gum made with...

Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has engaged French organisation Eurofins Scientific to manufacture its medicated chewable products designed to treat nicotine and opioid addiction disorders. Marketed unde...

The Creso Pharma Ltd (ASX: CPH) share price is soaring 40% today. However, earlier, the company’s share price exploded 70%. ASX cannabis shares Incannex Healthcare Ltd (ASX: IHL) and Bod Australia Ltd (ASX: BOD) are also up 6% and 14% re...

Incannex Healthcare (IHL) initiates a study to assess the effects and tolerability of its drug for obstructive sleep apnoeaCMAX Clinical Research and Novotech CRO will complete a bioavalability and bioequivalence study assessing the pharmac...

Clinical-stage medicinal cannabis and psychedelic pharmaceutical company Incannex Healthcare (ASX: IHL) has initiated a BA/BE (bioavailability/bioequivalence) clinical trial evaluating IHL-42X in obstructive sleep apnoea (OSA). Incannex wil...

ASX cannabis shares haven’t exactly been smoking hot this year. That’s partly because similar headwinds facing cannabis stocks worldwide have hit the sector. Firstly, there’s rocketing interest rates. Higher rates have hit growth sha...

The Incannex Healthcare Ltd (ASX: IHL) share price went up in smoke in October, underperforming the S&P/ASX 300 Index (ASX: XKO) by 15% over the course of the month. That was despite plenty of seemingly positive news being released by...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. Cybersecurity, biotech and adtech companies were some that posted positive results today. Here’s some of the reports which have caugh...

Incannex Healthcare (ASX: IHL) has made several advances across its portfolio of cannabinoid and psychedelic medical therapies including generating positive preliminary safety and tolerability results of its anti-inflammatory drug IHL-675A...

Germany looks to legalise recreational cannabis and US and Canadian companies are paying attention  Neurotech reports success with its cannabis-based drug for paediatric autism symptoms  ECS Botanics has sold its Tasmanian business and a...

Amid a worldwide surge of interest in using psychedelic substances to treat stubborn mental health conditions, the ASX possibly soon could host its first pure-play drug developer in this (mind) expanding field. The private Woke Pharmaceutic...

After completing patient dosing in its Phase 1 clinical trial of anti-inflammatory IHL-675A, Incannex Healthcare has advanced to Phase 2 trials. Clinical stage pharmaceutical cannabinoid and psychedelics company Incannex Healthcare (ASX:IHL...

Incannex Healthcare (IHL) is gearing up to launch two second-phase clinical studies of its IHL-675A anti-inflammatory drugThis follows a successful phase one study of the drug that found it to be well-tolerated, with no recorded adverse eve...

Incannex Healthcare (ASX: IHL) has completed the dosing of healthy volunteer participants in a phase 1 clinical trial to assess the safety of its multi-use anti-inflammatory drug IHL-675A. The trial is measuring the safety and tolerability...

Incannex Healthcare (IHL) completes a pre-investigational new drug application meeting with the US FDA for its IHL-216A drugThe company says the FDA provided critical guidance on the data requirements for opening an IND for the drug which a...

Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug (IND) application meeting with the US Food and Drug Administration over IHL-216A, its proprietary drug for the treatment of tr...

ASX cannabis shares have leapt back onto investor radars and are likely to grab more media headlines in the weeks ahead. While all three are deep in the red today amid wider selling action that sees the All Ordinaries Index (ASX: XAO) down...

Healthcare share Incannex Healthcare Ltd (ASX: IHL) was added to the S&P/ASX 300 Index (ASX: XKO) last month. The company is a clinical-stage pharmaceutical company with a focus on developing medicinal cannabinoid products and psychede...

The Incannex Healthcare Ltd (ASX: IHL) share price has been on a roll lately. It has rocketed 21.4% over the last fortnight despite no price-sensitive news having been released by the clinical stage developer of medicinal cannabinoid pharm...

Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index   It turns out that the lazy stoner stereotype is actually a myth,...

The Incannex Healthcare Ltd (ASX: IHL) share price has had a tough 2022, losing 50% of its value year to date. That’s far lower than the S&P/ASX 200 Health Care Index (ASX: XHJ), which is down 5.24% for the same period. However, Incann...

Incannex Healthcare has been promoted to the big league. Clinical stage pharmaceutical cannabinoid and psychedelics company Incannex Healthcare (ASX:IHL) has achieved a milestone with its inclusion in the S&P/ASX300 index. Inclusion wi...

Shares in Incannex Healthcare Ltd (ASX: IHL) roared higher to close the market on Monday. Incannex shares closed the day up 13.04% to 26 cents apiece. In comparison, the All Ordinaries (ASX: XAO) finished the day up 0.26%. Why are Inca...

At last the pot stocks are paying dividends. Not metaphorically either. Cronos Australia (ASX: CAU) has broken the green ceiling on Monday, making the local industry’s first full year profit and damn it if I haven’t been smoking something –...

The Incannex Healthcare Ltd (ASX: IHL) share price has curled up in recent weeks, having bounced from yearly lows of 19 cents on 1 August. At the time of writing, it is priced at 31 cents apiece, ready to open the session on Friday. Mean...

Incannex has appointed a former Pfizer and now Novo Nordisk A/S executive to its board to help steer regulatory approvals for its key cannabinoid and psychedelic medicinal therapies. Clinical stage pharmaceutical cannabinoid and psychedeli...

ASX cannabis shares have been mixed performers on the market in the year to date, but are there better days ahead? Cannabis shares on the ASX include Cronos Australia Ltd (ASX: CAU), Incannex Healthcare Ltd (ASX: IHL), Emyria Ltd (ASX: E...

Incannex Healthcare (ASX: IHL) has appointed experienced pharmaceutical executive Robert B. Clark to its board of directors. Mr Clark is a strategic regulatory affairs expert with over 38 years of experience in US and global markets, includ...

Ice-T is opening a cannabis dispensary in New Jersey this year Snoop Dogg’s venture capital firm led a seed funding round for TSUMo Snacks Incannex ramps up development and manufacturing of IHL-216A drug New Jersey has given Ice-T the gre...

The Incannex Healthcare Ltd (ASX: IHL) share price has jumped from the opening gate on Tuesday. At the time of writing, Incannex was trading nearly 8% higher at 28 cents a share following the release of a company presentation. It’s a wel...

ASX cannabis share Incannex Healthcare Ltd (ASX: IHL) has caught a bid last week, reversing off 52-week lows to now trade 36% higher on the month. Just after the open on Monday, Incannex is priced at 27.5 cents – not far off its yearl...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a high. At the time of writing, the benchmark index is up 0.5% to 7,010.7 points. Four ASX shares that are climbing more than most today are listed b...

ShareCafeLunch Report: 5 August, 2022 by Tim McGowen   Gold stocks are stronger across the board as the price of gold reaches one month highs as the $US weakens and geopolitical tensions rise with China & Taiwan. The annual Diggers &amp...

Incannex Healthcare (ASX: IHL) now officially owns the world’s largest portfolio of patented medicinal cannabinoid drug formulations, following the completed acquisition of APIRx Pharmaceuticals. The acquisition was announced in March this...

Incannex Healthcare (IHL) finalises its $125 million acquisition of APIRx Pharmaceuticals Stakeholders of APIRx were issued more than 218 million new shares in IHL at 57 cents per share, representing a premium of over 59 per cent to when t...

The ASX is set to open higher on Friday Wall Street was mixed overnight ahead of the US non-farm payrolls Shares in Block Inc on NYSE fall 7% on volumes miss Local shares are set to open higher today. At 8am AEDT, the ASX 200 August futur...

Leading Australian medicinal cannabis company Incannex (ASX: IHL) has today completed the acquisition of APIRx - a US biotech outfit with intellectual property (IP) in the cannabis space - for $124 million. The deal brings the two firms to...

The Incannex Healthcare Ltd (ASX: IHL) share price has bounced from 52-week lows today and now trades in the green. At the time of writing, the share is swapping hands more than 5% higher at 20 cents apiece on no news. What’s up with th...

Incannex has moved to advance its inhaled drug product for the treatment of traumatic brain injury with a new development and manufacturing deal. Clinical-stage pharmaceutical company Incannex Healthcare (ASX:IHL) has announced it has enga...

Incannex Healthcare (IHL) engages research, development and manufacturing organisation Curia Global to develop and manufacture GMP-Grade IHL-216A Curia will generate data regarding the quality and stability of IHL-216A to support future re...

Incannex Healthcare (ASX: IHL) has announced it has engaged contract research, development, and manufacturing firm Curia Global to scale up the manufacture of its proprietary pharmaceutical cannabis-based product IHL-216A for the treatment...

Mysterious pink glow over Mildura Thailand businesses go nuts for CBD desserts and bubble tea ECS nabs $2m commercial loan facility to invest in new capacity ICYMI a mysterious pink glow above Mildura sent residents into a bit of a frenzy...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they...

Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has provided an extensive update its latest quarterly report. The company made progress in pre-clinical and clinical trials of three cannabinoid drugs and one psychedelic...

In the June quarter, Incannex Healthcare (IHL) progressed several clinical trials ahead of submitting investigational new drug applications to the US FDA Incannex reported positive data from its cannabidiol drug, IHL-42X, in patients with...